Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fa-Chyi Lee

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsChristopher J Sweeney, E Gabriela Chiorean, Claire F Verschraegen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 18, 2024
Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic CancerClaudia Rosso, Naomie Devico Marciano, Deepika Nathan, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2015
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapiesVincent J Picozzi, Ramesh K Ramanathan, Maeve A Lowery, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsChristopher J Sweeney, E Gabriela Chiorean, Claire F Verschraegen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 18, 2024
Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic CancerClaudia Rosso, Naomie Devico Marciano, Deepika Nathan, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2015
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapiesVincent J Picozzi, Ramesh K Ramanathan, Maeve A Lowery, et al.
Pageof 4